Intra-arterial idarubicin_lipiodol without embolisation in hepatocellular carcinoma: The LIDA-B phase I trial.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of hepatology"
DOI: 10.1016/j.jhep.2018.01.022
Abstract: BACKGROUND & AIMS Idarubicin shows high cytotoxicity against hepatocellular carcinoma (HCC) cells, a high hepatic extraction ratio, and high lipophilicity leading to stable emulsions with lipiodol. A dose-escalation phase I trial of idarubicin_lipiodol (without embolisation)… read more here.
Keywords: idarubicin; idarubicin lipiodol; without embolisation; phase trial ... See more keywords